Actively Recruiting

Age: 1Year - 18Years
All Genders
NCT03190538

Nonalcoholic Steatohepatitis in Chinese Children

Led by Humanity and Health Research Centre · Updated on 2025-03-24

400

Participants Needed

1

Research Sites

578 weeks

Total Duration

On this page

Sponsors

H

Humanity and Health Research Centre

Lead Sponsor

B

Beijing 302 Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Nonalcoholic steatohepatitis (NASH) is now recognised as an increasing clinical problem in children. Steatosis without significant liver cell injury or fibrosis is the most common form of nonalcoholic fatty liver disease (NAFLD) in both adults and children. Studies in the adult population have variably suggested that steatosis is a benign nonprogressive condition and NASH is recognised as a potentially serious condition with significantly risk of morbidity and mortality. A growing body of evidence suggests that children with NASH frequently show histopathological features that differ from those of adults. The prevalence of this pattern in a wide range of paediatric cases as well as other histopathological lesions and their relevance and prognostic significance in children with NAFLD remains to be determined. Thus the investigators would like to conduct a study of biopsies and clinical information to document the histological features of paediatric NAFLD, to explore the natural history of paediatric NAFLD, and to determine the frequency and prognostic value of these features.

CONDITIONS

Official Title

Nonalcoholic Steatohepatitis in Chinese Children

Who Can Participate

Age: 1Year - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 1 to 18 years with biopsy-proven nonalcoholic fatty liver disease (NAFLD)
  • Alcohol consumption less than 20 grams per day for boys and less than 10 grams per day for girls
Not Eligible

You will not qualify if you...

  • Diagnosis of viral hepatitis, such as HBV or HCV
  • Diagnosis of a1-anti-trypsin disease
  • Diagnosis of autoimmune hepatitis
  • Diagnosis of Wilson disease
  • Liver impairment caused by drugs

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Children's Liver Disease Center, 302 Hospital

Beijing, China

Actively Recruiting

Loading map...

Research Team

G

George Lau, MD, PhD

CONTACT

Y

Yudong Wang, MD, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here